The Summary
The TARGET-D trial investigated whether personalized vitamin D3 supplementation could reduce major cardiovascular events in heart attack survivors. Researchers randomized 630 patients with low vitamin D levels to either standard care or a targeted regimen, where doses were actively adjusted to maintain optimal blood levels (40 to 80 ng/mL). Over a four-year follow-up, the personalized vitamin D strategy did not significantly reduce the overall composite risk of death, repeat heart attack, stroke, or heart failure hospitalization compared to standard care, although a secondary analysis noted a potential reduction in repeat heart attacks.
Why this is interesting
While observational studies link low vitamin D to heart disease, clinical trials using fixed doses have failed to show benefits. TARGET-D tested a smarter approach by tailoring doses to individual blood levels. Despite this personalized method, the therapy still failed to significantly prevent major cardiovascular complications overall. For consumers, this suggests that while maintaining adequate vitamin D is good for general health, high-dose targeted supplementation is not a magic shield against recurrent heart issues, reinforcing the need to focus on established cardiac therapies instead.